Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Reports: GlaxoSmithKline | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Reports: GlaxoSmithKline

Pharma & Vaccines up 6% in 4Q13

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

GlaxoSmithKline 4Q13

4Q Revenues: £6.9 billion (+2%)

4Q Earnings: £2.5 billion (+205%)

FY Revenues: £26.5 billion (flat)

FY Earnings: £5.6 billion (+20%)

Comments: Sales of Pharmaceuticals and Vaccines (P&V) rose 6% in 4Q to £5.7 billion, and were up 1% for FY to £21.3 billion. Consumer Healthcare sales were flat at £1.2 billion for 4Q and up 2% to £5.3 billion for FY. Respiratory revenues were up 7% (CER) to £2.0 billion in 4Q and up 4% to £7.5 billion in FY, driven by increases in Seretide/Advair sales (+4% to £5.3 billion in FY). CNS sales fell 8% in FY to £1.5 billion, as Paxil faced generic competition in Japan and Europe and Requip and Lamictal XR faced generics in the U.S. Oncology sales grew 22% in FY to £969 million and 24% in 4Q to £266 million, led by Votrient, Promacta and Arzerra, as well as new products in metastatic melanoma: Tafinlar and Mekinist. Sales of Benlysta in 4Q were up 28% to £46 million.

All results in GBP. Exchange rate is 1.63 GBP to $1.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters